Acceleration of HDL-Mediated Cholesterol Efflux Alleviates Periodontitis

Area of Science:

• Oral Biology
• Metabolic Disorders
• Inflammation Research

Background:

• Periodontitis (PD) is a prevalent inflammatory condition frequently linked to metabolic disorders like hyperlipidemia.
• Hypercholesterolemia is identified as a significant predisposing factor for PD development.
• Logistic regression confirms a strong positive association between PD and dyslipidemia.

Purpose of the Study:

• To investigate the role of excess cholesterol in PD pathogenesis.
• To evaluate the efficacy of cholesterol-lowering drugs in mitigating PD.
• To explore the mechanism of cholesterol efflux in regulating periodontal inflammation and bone erosion.

Main Methods:

• In vivo studies using a PD mouse model fed a high-cholesterol diet.
• In vitro experiments involving cholesterol treatment of gingival fibroblasts (GFs).
• Comparative analysis of cholesterol-lowering drugs (e.g., fenofibrate) and assessment of apoA-I binding protein (APOA1BP) expression and function.

Main Results:

• Excess cholesterol influx into GFs contributes to periodontal inflammation and alveolar bone erosion.
• Fenofibrate demonstrated the most significant protective effect against PD pathogenesis by increasing high-density lipoprotein cholesterol.
• Cholesterol efflux, regulated by APOA1BP, was suppressed in PD but restored upon APOA1BP overexpression, reducing inflammation and bone loss.

Conclusions:

• Hypercholesterolemia is a risk factor for periodontitis.
• Cholesterol-lowering medications, particularly fenofibrate, may offer therapeutic benefits for PD.
• Enhancing high-density lipoprotein-mediated cholesterol efflux via APOA1BP presents a potential novel therapeutic strategy for PD.